Alaproclate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Alaproclate
Accession Number
DB13233
Type
Small Molecule
Groups
Experimental
Description

Alaproclate is a drug that was being developed as an antidepressant by the Swedish pharmaceutical company Astra AB (now AstraZeneca) in the 1970s. It acts as a selective serotonin reuptake inhibitor (SSRI), and along with zimelidine and indalpine, was one of the first of its kind. Development was discontinued due to the observation of liver complications in rodent studies. In addition to its SSRI properties, alaproclate has been found to act as a non-competitive NMDA receptor antagonist, but does not have discriminative stimulus properties similar to phencyclidine.

Structure
Thumb
Synonyms
Not Available
External IDs
GEA 654 / GEA-654
Product Ingredients
IngredientUNIICASInChI Key
Alaproclate hydrochlorideNIH506S9US60719-83-7OPAKSOWFKIUFNP-UHFFFAOYSA-N
Categories
UNII
C4R42570ZO
CAS number
60719-82-6
Weight
Average: 255.74
Monoisotopic: 255.1026065
Chemical Formula
C13H18ClNO2
InChI Key
FZSPJBYOKQPKCD-UHFFFAOYSA-N
InChI
InChI=1S/C13H18ClNO2/c1-9(15)12(16)17-13(2,3)8-10-4-6-11(14)7-5-10/h4-7,9H,8,15H2,1-3H3
IUPAC Name
1-(4-chlorophenyl)-2-methylpropan-2-yl 2-aminopropanoate
SMILES
CC(N)C(=O)OC(C)(C)CC1=CC=C(Cl)C=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Alaproclate.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Alaproclate is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcarboseAlaproclate may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Alaproclate.Approved
AcenocoumarolAlaproclate may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Alaproclate.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Alaproclate.Approved
Acetylsalicylic acidAlaproclate may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Alaproclate.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Alaproclate.Approved, Investigational
AlbiglutideAlaproclate may increase the hypoglycemic activities of Albiglutide.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Alaproclate.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Alaproclate.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Alaproclate.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Alaproclate.Investigational
AlogliptinAlaproclate may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Alaproclate.Experimental, Illicit
AlphaprodineAlphaprodine may increase the serotonergic activities of Alaproclate.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Alaproclate.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Alaproclate.Approved, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Alaproclate.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Alaproclate.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Alaproclate.Approved, Illicit
AmoxapineAlaproclate may increase the serotonergic activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Alaproclate.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Alaproclate is combined with Amphetamine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Alaproclate.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Alaproclate.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Alaproclate.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Alaproclate.Approved
AtenololThe serum concentration of Atenolol can be increased when it is combined with Alaproclate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Alaproclate.Investigational, Vet Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Alaproclate.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Alaproclate.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Alaproclate.Illicit
BefunololThe serum concentration of Befunolol can be increased when it is combined with Alaproclate.Experimental
BendroflumethiazideAlaproclate may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Alaproclate is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Alaproclate.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Alaproclate.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Alaproclate.Approved
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Alaproclate.Approved
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Alaproclate.Approved
BezitramideBezitramide may increase the serotonergic activities of Alaproclate.Experimental, Illicit, Withdrawn
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Alaproclate.Approved
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Alaproclate.Investigational
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Alaproclate.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Alaproclate.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Alaproclate.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Alaproclate is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Alaproclate.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Alaproclate.Experimental
BromocriptineAlaproclate may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Alaproclate.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Alaproclate.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Alaproclate.Approved, Investigational, Withdrawn
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Alaproclate.Investigational
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Alaproclate.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Alaproclate.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Alaproclate.Approved
BuprenorphineBuprenorphine may increase the serotonergic activities of Alaproclate.Approved, Illicit, Investigational, Vet Approved
BuspironeBuspirone may increase the serotonergic activities of Alaproclate.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Alaproclate.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Alaproclate.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Alaproclate.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Alaproclate.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Alaproclate.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Alaproclate.Approved, Illicit, Vet Approved
CanagliflozinAlaproclate may increase the hypoglycemic activities of Canagliflozin.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Alaproclate.Investigational
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Alaproclate.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Alaproclate.Approved
CarfentanilCarfentanil may increase the serotonergic activities of Alaproclate.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Alaproclate.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Alaproclate is combined with Caroxazone.Withdrawn
CarteololThe serum concentration of Carteolol can be increased when it is combined with Alaproclate.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Alaproclate.Approved, Investigational
CelecoxibAlaproclate may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Alaproclate.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Alaproclate.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Alaproclate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Alaproclate.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Alaproclate.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Alaproclate.Approved
ChlorothiazideAlaproclate may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Alaproclate.Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Alaproclate.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Alaproclate.Approved, Vet Approved
ChlorpropamideAlaproclate may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Alaproclate.Approved, Investigational, Withdrawn
ChlorthalidoneAlaproclate may increase the hyponatremic activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Alaproclate.Approved
CimetidineThe metabolism of Alaproclate can be decreased when combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Alaproclate.Approved, Vet Approved
CitalopramCitalopram may increase the serotonergic activities of Alaproclate.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Alaproclate.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Alaproclate.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Alaproclate.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Alaproclate.Investigational
ClomipramineAlaproclate may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Alaproclate.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Alaproclate.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Alaproclate.Experimental
CloranololThe serum concentration of Cloranolol can be increased when it is combined with Alaproclate.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Alaproclate.Approved, Illicit
ClorindioneAlaproclate may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Alaproclate.Experimental
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Alaproclate.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Alaproclate.Approved, Illicit
CodeineCodeine may increase the serotonergic activities of Alaproclate.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Alaproclate.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Alaproclate.Approved
CyclopenthiazideAlaproclate may increase the hyponatremic activities of Cyclopenthiazide.Experimental
CyproheptadineThe therapeutic efficacy of Alaproclate can be decreased when used in combination with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Alaproclate.Approved
DapagliflozinAlaproclate may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Alaproclate.Approved
DapoxetineDapoxetine may increase the serotonergic activities of Alaproclate.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Alaproclate.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Alaproclate.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Alaproclate.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Alaproclate.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Alaproclate is combined with Desmopressin.Approved
DesvenlafaxineDesvenlafaxine may increase the serotonergic activities of Alaproclate.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Alaproclate.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alaproclate.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Alaproclate.Approved, Vet Approved
DextromethorphanAlaproclate may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Alaproclate.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Alaproclate.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the serotonergic activities of Alaproclate.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Alaproclate.Approved, Illicit, Vet Approved
DicoumarolAlaproclate may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Alaproclate.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Alaproclate.Approved, Illicit
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Alaproclate.Approved, Illicit
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Alaproclate.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Alaproclate.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Alaproclate.Approved
DiphenadioneAlaproclate may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Alaproclate.Approved
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Alaproclate.Approved, Illicit
DisopyramideAlaproclate may increase the hypoglycemic activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Alaproclate.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Alaproclate.Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Alaproclate.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Alaproclate.Approved
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Alaproclate.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Alaproclate.Experimental
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Alaproclate.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Alaproclate.Experimental, Illicit
DulaglutideAlaproclate may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineDuloxetine may increase the serotonergic activities of Alaproclate.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Alaproclate.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Alaproclate.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Alaproclate.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Alaproclate.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Alaproclate.Investigational
EmpagliflozinAlaproclate may increase the hypoglycemic activities of Empagliflozin.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Alaproclate.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Alaproclate.Approved, Investigational
EpanololThe serum concentration of Epanolol can be increased when it is combined with Alaproclate.Experimental
EscitalopramEscitalopram may increase the serotonergic activities of Alaproclate.Approved, Investigational
EsmololThe serum concentration of Esmolol can be increased when it is combined with Alaproclate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Alaproclate.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Alaproclate.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Alaproclate.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alaproclate.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Alaproclate.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Alaproclate.Approved
Ethyl biscoumacetateAlaproclate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Alaproclate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Alaproclate.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Alaproclate.Approved, Illicit
EthylmorphineEthylmorphine may increase the serotonergic activities of Alaproclate.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Alaproclate.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Alaproclate.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Alaproclate.Approved
EtodolacAlaproclate may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Alaproclate.Approved
EtoperidoneEtoperidone may increase the serotonergic activities of Alaproclate.Withdrawn
EtoricoxibAlaproclate may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Alaproclate.Illicit, Vet Approved
ExenatideAlaproclate may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Alaproclate.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Alaproclate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Alaproclate.Approved, Illicit, Withdrawn
FenfluramineAlaproclate may increase the serotonergic activities of Fenfluramine.Illicit, Investigational, Withdrawn
FentanylFentanyl may increase the serotonergic activities of Alaproclate.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Alaproclate.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Alaproclate.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Alaproclate.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Alaproclate.Approved, Illicit
FluindioneAlaproclate may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Alaproclate.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Alaproclate.Approved, Illicit
FluoxetineFluoxetine may increase the serotonergic activities of Alaproclate.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Alaproclate.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Alaproclate.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Alaproclate.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Alaproclate.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Alaproclate.Approved
FluvoxamineFluvoxamine may increase the serotonergic activities of Alaproclate.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Alaproclate.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Alaproclate.Approved, Illicit, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Alaproclate is combined with Furazolidone.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Alaproclate.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Alaproclate.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Alaproclate.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Alaproclate.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Alaproclate.Investigational
GliclazideAlaproclate may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideAlaproclate may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideAlaproclate may increase the hypoglycemic activities of Glipizide.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Alaproclate.Approved, Illicit
GlyburideAlaproclate may increase the hypoglycemic activities of Glyburide.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Alaproclate.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Alaproclate.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Alaproclate.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Alaproclate.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Alaproclate is combined with Harmaline.Experimental
HeroinHeroin may increase the serotonergic activities of Alaproclate.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Alaproclate.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Alaproclate is combined with Hydracarbazine.Experimental
HydrochlorothiazideAlaproclate may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneHydrocodone may increase the serotonergic activities of Alaproclate.Approved, Illicit
HydroflumethiazideAlaproclate may increase the hyponatremic activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneHydromorphone may increase the serotonergic activities of Alaproclate.Approved, Illicit
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Alaproclate.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Alaproclate.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Alaproclate.Approved
IndalpineIndalpine may increase the serotonergic activities of Alaproclate.Investigational, Withdrawn
IndapamideAlaproclate may increase the hyponatremic activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Alaproclate.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Alaproclate.Investigational
Insulin AspartAlaproclate may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirAlaproclate may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineAlaproclate may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineAlaproclate may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanAlaproclate may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproAlaproclate may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Alaproclate.Approved, Investigational
Ioflupane I-123Alaproclate may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideThe risk or severity of adverse effects can be increased when Alaproclate is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Alaproclate is combined with Iproniazid.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Alaproclate is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Alaproclate.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Alaproclate.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Alaproclate.Approved
KetobemidoneKetobemidone may increase the serotonergic activities of Alaproclate.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Alaproclate.Approved, Nutraceutical, Withdrawn
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Alaproclate.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Alaproclate.Approved, Investigational
LandiololThe serum concentration of Landiolol can be increased when it is combined with Alaproclate.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Alaproclate.Approved, Investigational
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Alaproclate.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Alaproclate.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Alaproclate.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Alaproclate.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Alaproclate.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Alaproclate.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Alaproclate.Approved
LevorphanolLevorphanol may increase the serotonergic activities of Alaproclate.Approved
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Alaproclate.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Alaproclate.Approved, Vet Approved
LinezolidLinezolid may increase the serotonergic activities of Alaproclate.Approved, Investigational
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Alaproclate.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Alaproclate.Approved
LiraglutideAlaproclate may increase the hypoglycemic activities of Liraglutide.Approved
LithiumLithium may increase the serotonergic activities of Alaproclate.Approved
LofentanilLofentanil may increase the serotonergic activities of Alaproclate.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Alaproclate.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Alaproclate.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Alaproclate.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Alaproclate.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Alaproclate.Approved
LumiracoxibAlaproclate may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Alaproclate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Alaproclate.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Alaproclate.Approved
MebanazineThe risk or severity of adverse effects can be increased when Alaproclate is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Alaproclate.Experimental
MecaserminAlaproclate may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Alaproclate.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Alaproclate.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Alaproclate.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Alaproclate.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Alaproclate.Approved, Investigational
MepindololThe serum concentration of Mepindolol can be increased when it is combined with Alaproclate.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Alaproclate.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Alaproclate.Approved, Illicit
MeptazinolMeptazinol may increase the serotonergic activities of Alaproclate.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Alaproclate.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Alaproclate.Approved
MetforminAlaproclate may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Alaproclate.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Alaproclate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Alaproclate.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Alaproclate.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Alaproclate.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Alaproclate.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Alaproclate.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Alaproclate.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Alaproclate.Approved
MethyclothiazideAlaproclate may increase the hyponatremic activities of Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Alaproclate.Experimental
Methylene blueAlaproclate may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Alaproclate.Approved
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Alaproclate.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Alaproclate.Approved, Investigational
MetolazoneAlaproclate may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Alaproclate.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Alaproclate.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Alaproclate.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Alaproclate.Approved, Illicit
MifepristoneAlaproclate may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolAlaproclate may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranMilnacipran may increase the serotonergic activities of Alaproclate.Approved
MinaprineThe risk or severity of adverse effects can be increased when Alaproclate is combined with Minaprine.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Alaproclate.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Alaproclate is combined with Moclobemide.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Alaproclate.Approved
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Alaproclate.Approved, Investigational, Withdrawn
MorphineMorphine may increase the serotonergic activities of Alaproclate.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Alaproclate.Approved, Investigational
NabumetoneAlaproclate may increase the antiplatelet activities of Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Alaproclate.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Alaproclate.Approved
NateglinideAlaproclate may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Alaproclate.Approved, Investigational
NefazodoneNefazodone may increase the serotonergic activities of Alaproclate.Approved, Withdrawn
NialamideThe risk or severity of adverse effects can be increased when Alaproclate is combined with Nialamide.Withdrawn
NicomorphineNicomorphine may increase the serotonergic activities of Alaproclate.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Alaproclate.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Alaproclate.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Alaproclate.Investigational
NormethadoneNormethadone may increase the serotonergic activities of Alaproclate.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Alaproclate.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Alaproclate is combined with Octamoxin.Withdrawn
OlanzapineAlaproclate may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alaproclate.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Alaproclate.Approved
OpiumOpium may increase the serotonergic activities of Alaproclate.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Alaproclate.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Alaproclate.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Alaproclate.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Alaproclate.Approved, Investigational
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Alaproclate.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Alaproclate.Approved
OxycodoneOxycodone may increase the serotonergic activities of Alaproclate.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the serotonergic activities of Alaproclate.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Alaproclate.Approved
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Alaproclate.Approved, Investigational
ParecoxibAlaproclate may increase the antiplatelet activities of Parecoxib.Approved
PargylineThe risk or severity of adverse effects can be increased when Alaproclate is combined with Pargyline.Approved
ParoxetineParoxetine may increase the serotonergic activities of Alaproclate.Approved, Investigational
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Alaproclate.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Alaproclate.Experimental
PentamidineAlaproclate may increase the hypoglycemic activities of Pentamidine.Approved
PentazocinePentazocine may increase the serotonergic activities of Alaproclate.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Alaproclate.Approved, Vet Approved
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Alaproclate.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Alaproclate.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Alaproclate.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Alaproclate.Approved
PethidinePethidine may increase the serotonergic activities of Alaproclate.Approved
PhenazocinePhenazocine may increase the serotonergic activities of Alaproclate.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Alaproclate is combined with Phenelzine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Alaproclate.Experimental
PhenindioneAlaproclate may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazineThe risk or severity of adverse effects can be increased when Alaproclate is combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Alaproclate.Approved
PhenoperidinePhenoperidine may increase the serotonergic activities of Alaproclate.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Alaproclate.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Alaproclate is combined with Phenoxypropazine.Withdrawn
PhenprocoumonAlaproclate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Alaproclate.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Alaproclate is combined with Pimozide.Approved
PindololThe serum concentration of Pindolol can be increased when it is combined with Alaproclate.Approved
PioglitazoneAlaproclate may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Alaproclate.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Alaproclate.Approved, Investigational
PiritramidePiritramide may increase the serotonergic activities of Alaproclate.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Alaproclate is combined with Pirlindole.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Alaproclate is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Alaproclate.Approved
Platelet Activating FactorThe serum concentration of Platelet Activating Factor can be increased when it is combined with Alaproclate.Experimental
PolythiazideAlaproclate may increase the hyponatremic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Alaproclate.Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Alaproclate.Approved
PramlintideAlaproclate may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Alaproclate.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Alaproclate.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Alaproclate.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Alaproclate.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Alaproclate.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Alaproclate.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Alaproclate is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Alaproclate.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Alaproclate.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Alaproclate.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Alaproclate.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Alaproclate.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Alaproclate.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Alaproclate.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Alaproclate.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Alaproclate.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Alaproclate.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Alaproclate.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Alaproclate.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Alaproclate.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Alaproclate.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Alaproclate.Approved
QuinethazoneAlaproclate may increase the hyponatremic activities of Quinethazone.Approved
QuinineAlaproclate may increase the hypoglycemic activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Alaproclate.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Alaproclate.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Alaproclate.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Alaproclate is combined with Rasagiline.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Alaproclate.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Alaproclate.Approved, Withdrawn
RepaglinideAlaproclate may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Alaproclate.Approved, Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Alaproclate.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Alaproclate.Investigational
RofecoxibAlaproclate may increase the antiplatelet activities of Rofecoxib.Investigational, Withdrawn
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Alaproclate.Vet Approved
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Alaproclate.Approved
RosiglitazoneAlaproclate may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Alaproclate is combined with Safrazine.Withdrawn
SaxagliptinAlaproclate may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Alaproclate.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Alaproclate.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Alaproclate is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Alaproclate.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Alaproclate.Approved, Investigational, Withdrawn
SertralineSertraline may increase the serotonergic activities of Alaproclate.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Alaproclate.Approved, Vet Approved
SitagliptinAlaproclate may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Alaproclate.Approved
SotalolThe serum concentration of Sotalol can be increased when it is combined with Alaproclate.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Alaproclate.Approved
SufentanilSufentanil may increase the serotonergic activities of Alaproclate.Approved, Investigational
SulfadiazineAlaproclate may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleAlaproclate may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleAlaproclate may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Alaproclate.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Alaproclate.Experimental
SunitinibAlaproclate may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Alaproclate.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Alaproclate.Approved, Investigational
TalinololThe serum concentration of Talinolol can be increased when it is combined with Alaproclate.Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Alaproclate.Investigational
TapentadolTapentadol may increase the serotonergic activities of Alaproclate.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Alaproclate.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Alaproclate.Approved
TertatololThe serum concentration of Tertatolol can be increased when it is combined with Alaproclate.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Alaproclate.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Alaproclate.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Alaproclate.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Alaproclate.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Alaproclate.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Alaproclate.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Alaproclate.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Alaproclate.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Alaproclate.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Alaproclate.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Alaproclate.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Alaproclate.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Alaproclate.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Alaproclate.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Alaproclate.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Alaproclate.Vet Approved
TilidineTilidine may increase the serotonergic activities of Alaproclate.Experimental
TimololThe serum concentration of Timolol can be increased when it is combined with Alaproclate.Approved
TioclomarolAlaproclate may increase the anticoagulant activities of Tioclomarol.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Alaproclate.Approved
TolazamideAlaproclate may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideAlaproclate may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Alaproclate.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Alaproclate is combined with Toloxatone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Alaproclate.Approved
TramadolAlaproclate may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Alaproclate.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Alaproclate.Approved
TrazodoneAlaproclate may increase the serotonergic activities of Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Alaproclate.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Alaproclate.Vet Approved
TrichlormethiazideAlaproclate may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Alaproclate.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Alaproclate.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Alaproclate.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Alaproclate.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Alaproclate.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Alaproclate.Approved
ValdecoxibAlaproclate may increase the antiplatelet activities of Valdecoxib.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Alaproclate.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Alaproclate.Approved
VenlafaxineVenlafaxine may increase the serotonergic activities of Alaproclate.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Alaproclate.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Alaproclate.Approved
VilazodoneAlaproclate may increase the serotonergic activities of Vilazodone.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Alaproclate.Experimental
VortioxetineAlaproclate may increase the serotonergic activities of Vortioxetine.Approved
WarfarinAlaproclate may increase the anticoagulant activities of Warfarin.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Alaproclate.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Alaproclate.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Alaproclate.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Alaproclate.Approved
ZimelidineZimelidine may increase the serotonergic activities of Alaproclate.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Alaproclate.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Alaproclate.Vet Approved
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Alaproclate.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Alaproclate.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Alaproclate.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Alaproclate.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Alaproclate.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Wilkinson A, Courtney M, Westlind-Danielsson A, Hallnemo G, Akerman KE: Alaproclate acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow. J Pharmacol Exp Ther. 1994 Dec;271(3):1314-9. [PubMed:7996440]
  2. Nicholson KL, Balster RL: Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats. Psychopharmacology (Berl). 2003 Nov;170(2):215-24. Epub 2003 Jul 8. [PubMed:12851738]
External Links
KEGG Drug
D02787
PubChem Compound
2081
PubChem Substance
347829288
ChemSpider
1997
BindingDB
76298
ChEBI
91544
ChEMBL
CHEMBL36591
Wikipedia
Alaproclate
ATC Codes
N06AB07 — Alaproclate

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0377 mg/mLALOGPS
logP2.82ALOGPS
logP2.88ChemAxon
logS-3.8ALOGPS
pKa (Strongest Basic)7.34ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area52.32 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity68.5 m3·mol-1ChemAxon
Polarizability26.99 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acid esters
Alternative Parents
Alanine and derivatives / Phenylpropanes / Chlorobenzenes / Aryl chlorides / Carboxylic acid esters / Monocarboxylic acids and derivatives / Organopnictogen compounds / Organochlorides / Organic oxides / Monoalkylamines
show 2 more
Substituents
Alpha-amino acid ester / Alanine or derivatives / Phenylpropane / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Benzenoid / Carboxylic acid ester
show 15 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on June 23, 2017 14:38 / Updated on December 01, 2017 17:37